Literature DB >> 20951665

Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo.

Thomas J Powell1, Naveen Palath, Mary E DeRome, Jie Tang, Andrea Jacobs, James G Boyd.   

Abstract

Nanoparticle vaccines induce potent immune responses in the absence of conventional adjuvant due to the recognition by immune cells of the particle structures, which mimic natural pathogens such as viruses and bacteria. Nanoparticle vaccines were fabricated by constructing artificial biofilms using layer-by-layer (LbL) deposition of oppositely charged polypeptides and target designed peptides on CaCO(3) cores. LbL nanoparticles were efficiently internalized by dendritic cells in vitro by a mechanism that was at least partially phagocytic, and induced DC maturation without triggering secretion of inflammatory cytokines. LbL nanoparticle delivery of designed peptides to DC resulted in potent cross-presentation to CD8+ T-cells and more efficient presentation to CD4+ T-cells compared to presentation of soluble peptide. A single immunization of mice with LbL nanoparticles containing designed peptide induced vigorous T-cell responses characterized by a balanced effector (IFNγ) and Th2 (IL-4) ELISPOT profile and in vivo CTL activity. Mice immunized with LbL nanoparticles bearing ovalbumin-derived designed peptides were protected from challenge with Listeria monocytogenes ectopically expressing ovalbumin, confirming the relevance of the CTL/effector T-cell responses. LbL nanoparticles also elicited antibody responses to the target epitope but not to the matrix components of the nanoparticle, avoiding the vector or carrier affect that hampers utility of other vaccine platforms. The potency and efficacy of LbL nanoparticles administered in aqueous suspension without adjuvant or other formulation additive, and the absence of immune responses to the matrix components, suggest that this strategy may be useful in producing novel vaccines against multiple diseases. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20951665     DOI: 10.1016/j.vaccine.2010.10.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT.

Authors:  Hee-Kwon Kim; Huiling Wei; Aditya Kulkarni; Roman M Pogranichniy; David H Thompson
Journal:  Biomacromolecules       Date:  2012-01-09       Impact factor: 6.988

2.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype.

Authors:  Stacey L Demento; Weiguo Cui; Jason M Criscione; Eric Stern; Jacob Tulipan; Susan M Kaech; Tarek M Fahmy
Journal:  Biomaterials       Date:  2012-04-06       Impact factor: 12.479

3.  Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.

Authors:  Thomas J Powell; Jie Tang; Mary E Derome; Robert A Mitchell; Andrea Jacobs; Yanhong Deng; Naveen Palath; Edwin Cardenas; James G Boyd; Elizabeth Nardin
Journal:  Vaccine       Date:  2013-02-26       Impact factor: 3.641

Review 4.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

5.  Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease.

Authors:  Patricia A Jorquera; Katie E Oakley; Thomas J Powell; Naveen Palath; James G Boyd; Ralph A Tripp
Journal:  Vaccines (Basel)       Date:  2015-10-12

6.  Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity.

Authors:  Claire Vanpouille-Box; François Hindré
Journal:  Front Oncol       Date:  2012-10-10       Impact factor: 6.244

Review 7.  Particles from preformed polymers as carriers for drug delivery.

Authors:  K Miladi; D Ibraheem; M Iqbal; S Sfar; H Fessi; A Elaissari
Journal:  EXCLI J       Date:  2014-02-03       Impact factor: 4.068

8.  Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Authors:  Patricia A Jorquera; Youngjoo Choi; Katie E Oakley; Thomas J Powell; James G Boyd; Naveen Palath; Lia M Haynes; Larry J Anderson; Ralph A Tripp
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

9.  C-type Lectin Receptors for Tumor Eradication: Future Directions.

Authors:  Ingeborg Streng-Ouwehand; Wendy W J Unger; Yvette Van Kooyk
Journal:  Cancers (Basel)       Date:  2011-08-08       Impact factor: 6.639

10.  The protein corona protects against size- and dose-dependent toxicity of amorphous silica nanoparticles.

Authors:  Dominic Docter; Christoph Bantz; Dana Westmeier; Hajo J Galla; Qiangbin Wang; James C Kirkpatrick; Peter Nielsen; Michael Maskos; Roland H Stauber
Journal:  Beilstein J Nanotechnol       Date:  2014-08-27       Impact factor: 3.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.